Headquartered in Washington, DC Fiscal year ends December NYSE: DHR danaher.com
Danaher Corporation is a global life sciences and diagnostics company that operates through three reporting segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment serves biopharmaceutical customers with bioprocessing technologies and solutions used to discover, develop, and manufacture therapies. The Life Sciences segment provides instruments, consumables, and services enabling scientific research, drug discovery, and clinical and applied testing. The Diagnostics segment offers clinical diagnostic products including molecular diagnostics and respiratory testing, as well as anatomic pathology solutions through its Leica Biosystems business. The company recently completed the acquisition of Masimo Corporation, expanding its diagnostics capabilities, and has announced its intention to acquire StatLab, a histology workflow products manufacturer. Danaher employs approximately 60,000 associates worldwide and operates under its proprietary Danaher Business System, a continuous improvement methodology applied across all its businesses to drive operational excellence. Updated
Danaher is moving from selling lab instruments to running the lab itself, putting its AI ambitions directly against drug-discovery software rivals.
JUST IN: Danaher unveils plans for an autonomous AI research lab combining robotics and AI to design, build, & test new molecules with minimal human intervention.
Three names in our 383-stock board closed with double-digit gains, led by Accenture's 15.6% jump to $211.97, a move that size is rare for a mega-cap consultant. The downside was far tamer, with AMC's 8.2% slide the worst of it.
Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not…
Abbott Laboratories has shed billions in market value this year while the broader market climbed, yet one analyst on Wall Street sees a dramatically different story unfolding beneath the surface of the…
Abbott and Danaher both reported Q1 2026 results, but the businesses underneath those numbers point in opposite directions, and choosing the wrong one right now costs more than just a few percentage…
Danaher (NYSE:DHR | DHR Price Prediction) is a stock built to own for 25 years because it supplies the irreplaceable plumbing of modern biologic drug manufacturing, and that position compounds quietly through…
Alex Sirois Pre-Market Stock Futures: Futures are trading lower on Tuesday, but the technology tsunami continued on Monday, as all major indices dipped into the red early on news that Iran was halting the…
Pre-Market Stock Futures: Futures are trading sharply lower as we get set to end one of the most exciting weeks on Wall Street in 25 years. Positive meetings in China with President…
Danaher (NYSE: DHR | DHR Price Prediction) is acquiring Masimo (NASDAQ: MASI) for $9.9 billion in an all-cash deal that values the medical technology company at $180 per share. The transaction, announced…
Danaher (NYSE: DHR | DHR Price Prediction) and Thermo Fisher Scientific (NYSE: TMO) both reported Q3 2025 earnings showing revenue growth around 5%, but underlying business momentum tells very different stories. Danaher…
Microsoft (NASDAQ:MSFT | MSFT Price Prediction) founder Bill gates is best-known for his founding of the most valuable company in the world (on multiple occasions, just not now). And rightfully so. That said,…
When ultra-rich investors start coalescing into the same names or put an unusually large amount of money into a single stock, that should raise more interest. That’s exactly what we’re seeing with…
24/7 Wall Street Insights Water is essential for life, and as such, water is and has been the most precious commodity on the planet since time immemorial. The stocks of companies involved…
Here is an assessment of how safe 3M’s dividend appears to be based on a variety of metrics. Is 3M about to lose its status as a Dividend King?
Tuesday's top analyst upgrades and downgrades included Apple, Baidu, Biogen, Comcast, Danaher, Estee Lauder, Exxon Mobil, General Motors, Otis Worldwide, Principal Financial and Zillow.
Thursday's top analyst upgrades and downgrades included Albertsons Companies, Alphabet, Apple, Coinbase Global, Danaher, Enphase Energy, GE HealthCare Technologies, General Electric, McDonald's, Microsoft, PulteGroup and Tesla.
Wednesday's top analyst upgrades and downgrades included Allstate, Amazon.com, Bath & Bodyworks, Danaher, Enterprise Products Partners, Marathon Petroleum, MGM Resorts, Microsoft, M&T Bank, NexTier Oilfield Solutions, Nike and Okta.
Danaher Corporation is a global life sciences and diagnostics company that operates through three reporting segments: Biotechnology, Life Sciences, and Diagnostics.
24/7 Wall St.'s 12-month price target for DHR is $265.67, rated Buy. The Wall Street consensus target is $241.00. DHR price prediction →
